RNXT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

335.50K

+680.23%

-0.083

-31.25%

516.67K

+162.27%

-0.100

+25%

-0.100

+25%

Estimates Revision

The market is revising Downward the revenue expectations for RenovoRx, Inc. (RNXT) for FY2025, with the revenue forecasts being adjusted by -8.16% over the past three months. During the same period, the stock price has changed by 0.00%.

Revenue Estimates for FY2025

Revise Downward

-8.16%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.59%

In Past 3 Month

Stock Price

No Change

0.00%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is 5.50 USD with a low forecast of 3.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

3.00

Averages

5.50

High

12.00

Current: 0.000

Low

3.00

Averages

5.50

High

12.00

Alliance Global

Buy

maintain

2025-11-14

Reason

Alliance Global

Price Target

2025-11-14

maintain

Buy

Reason

Alliance Global lowered the firm's price target on RenovoRx to $3 from $3.50 and keeps a Buy rating on the shares after the company reported Q3 earnings that were within expectations. The firm cites lower forecasts and modestly higher expected dilution for its reduced target.

Ascendiant

Edward Woo

Buy

maintain

$11

2025-06-05

Reason

Ascendiant

Edward Woo

Price Target

$11

2025-06-05

maintain

Buy

Reason

Ascendiant analyst Edward Woo raised the firm's price target on RenovoRx to $11.50 from $11 and keeps a Buy rating on the shares. The company reported Q1 results with strong revenue growth, the analyst tells investors in a research note. The firm says the RenovoCath commercialization and positive clinical data in Q3 will be "strong catalysts" for the stock.

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

2025-04-04

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-04-04

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Initiates

2025-03-27

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

2025-03-27

Initiates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for RenovoRx Inc (RNXT.O) is -2.18, compared to its 5-year average forward P/E of -3.00. For a more detailed relative valuation and DCF analysis to assess RenovoRx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.00

Current PE

-2.18

Overvalued PE

-1.36

Undervalued PE

-4.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.12

Current PS

12.74

Overvalued PS

13.59

Undervalued PS

-5.35

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

RNXT News & Events

Events Timeline

No data

News

3.5

01-08Globenewswire

Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044

9.5

01-08Benzinga

AZZ Inc Reports Q3 Earnings Beat, Shares Rise 2.1%

9.5

01-08NASDAQ.COM

ALX Oncology Gains 10.17% on Positive Phase 2 Trial Data for Evorpacept

People Also Watch

Frequently Asked Questions

What is RenovoRx Inc (RNXT) stock price today?

The current price of RNXT is 1.12 USD — it has decreased -2.61 % in the last trading day.

What is RenovoRx Inc (RNXT)'s business?

RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

What is the price predicton of RNXT Stock?

What is RenovoRx Inc (RNXT)'s revenue for the last quarter?

RenovoRx Inc revenue for the last quarter amounts to 266.00K USD, decreased % YoY.

What is RenovoRx Inc (RNXT)'s earnings per share (EPS) for the last quarter?

RenovoRx Inc. EPS for the last quarter amounts to -0.08 USD, decreased -20.00 % YoY.

What changes have occurred in the market's expectations for RenovoRx Inc (RNXT)'s fundamentals?

How many employees does RenovoRx Inc (RNXT). have?

RenovoRx Inc (RNXT) has 10 emplpoyees as of January 10 2026.

What is RenovoRx Inc (RNXT) market cap?

Today RNXT has the market capitalization of 41.05M USD.